CLINICAL_TRIALS
trial_result
· 2014-05-19
Clinical Trial Update: Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) [Phase 1]
Summary
Phase I trial evaluating the combination of ipilimumab and vemurafenib in BRAF-mutant melanoma terminated; results were posted in 2014.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Bristol-Myers Squibb | Conditions: Melanoma | Phase 1 | Status: TERMINATED | Results posted: 2014-05-19